The Aduhelm Files Damian Garde and Rachel Cohrs In wake of House investigation, 5 burning questions for FDA, Biogen, and Alzheimer’s treatments
The Aduhelm Files Rachel Cohrs, Adam Feuerstein and Damian Garde FDA, Biogen, and an Alzheimer’s drug approval: 8 key takeaways from congressional investigation
The Aduhelm Files Damian Garde and Adam Feuerstein Seeking maximum profits, Biogen set an ‘unjustifiably high price’ for Alzheimer’s treatment, investigation finds
Biotech Damian Garde Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say
Adam's Take Adam Feuerstein An Anavex study spin job sullies an otherwise spectacular Alzheimer’s conference
Biotech Damian Garde and Jonathan Wosen Detailed data on Alzheimer’s therapy from Eisai, Biogen hold up to scientific scrutiny
A STAT Investigation Jason Mast Death of patient in closely watched Alzheimer’s trial raises concern about risk for some groups
First Opinion Linda Goler Blount Better access to PET scans can help reduce racial inequities in Alzheimer’s disease
Pharmalot Ed Silverman Physicians group urges FDA to convene expert panel before finally approving an Alzheimer’s drug
Health Lauren Gravitz Scientists are finding increasing evidence for a link between air pollution and neurodegenerative diseases like Alzheimer’s
Biotech Adam Feuerstein FDA approves Alzheimer’s drug shown to moderately slow cognitive decline in early stages of the disease
The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein Listen: #JPM23, the future of Alzheimer’s, & rising Covid variants
The Aduhelm Files Rachel Cohrs ‘Rife with irregularities’: Congressional investigation reveals FDA’s approval of Aduhelm marked by secret discussions, breaches of protocol
Biotech Matthew Herper and Allison DeAngelis ‘This is not a cure’: Consensus begins to emerge on new Alzheimer’s drug
Biotech Jonathan Wosen and Damian Garde Alzheimer’s researchers try out an unfamiliar sensation: optimism
Biotech Damian Garde and Jonathan Wosen Roche’s failed Alzheimer’s studies lend weight to an emerging idea about potential treatments
First Opinion Madhav Thambisetty Anti-amyloid drugs and the mystery of treatment-associated brain shrinkage
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Listen: Roche’s failure, Eisai’s success, and a live AMA
Biotech Adam Feuerstein, Jason Mast and Damian Garde ‘We were right all along:’ For Japanese drugmaker Eisai, success against Alzheimer’s has been a long time coming
Health Usha Lee McFarling Brains of Black Americans age faster, study finds, with racial stressors a likely factor
First Opinion Poul Høilund-Carlsen, Abass Alavi and Jorge R. Barrio Better access to amyloid-PET scans won’t reduce racial inequities in Alzheimer’s disease
Biotech Adam Feuerstein and Damian Garde Roche’s experimental Alzheimer’s treatment fails to slow cognitive decline across two clinical trials
Health Usha Lee McFarling Cuando el cuidado es un asunto familiar, el Alzheimer supone una pesada carga para los hijos y los cónyuges
Health Usha Lee McFarling En la frontera entre Texas y México, nace un audaz plan para diversificar la investigación sobre el Alzheimer
Health Andrew Joseph ‘Front of the line’: For Alzheimer’s patients in successful trial, a feeling of gratitude
Biotech Adam Feuerstein and Damian Garde What to know about Roche’s experimental Alzheimer’s treatment
First Opinion Jason Karlawish How can the latest Alzheimer’s therapy reach patients? Follow this trustworthy process
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Listen: A surprise success in Alzheimer’s and how FDA history seeded modern controversy
Biotech Adam Feuerstein, Damian Garde and Rachel Cohrs Burning questions left unanswered about the latest Alzheimer’s therapy
Health Andrew Joseph An Alzheimer’s therapy scores winning results, but what could it mean for patients?